Quick Answer
Quince Therapeutics, Inc. reported Operating Income Loss of -$57.29 million for the year ending 2024.
- Quince Therapeutics, Inc. showed a decrease of -65.5% in Operating Income Loss from 2023 to 2024.
- This data is from Quince Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 24, 2025.
- XBRL data for this metric is available from 2018 to 2024 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$2.76 million | Q2 2018: -$2.64 million | Q3 2018: -$2.87 million | Q1 2019: -$6.08 million | Q2 2019: -$9.58 million | Q3 2019: -$10.57 million | Q1 2020: -$17.86 million | Q2 2020: -$18.27 million | Q3 2020: -$21.91 million | Q1 2021: -$23.31 million | Q2 2021: -$21.78 million | Q3 2021: -$21.68 million | Q1 2022: -$21.86 million | Q2 2022: -$16.26 million | Q3 2022: -$7.62 million | Q1 2023: -$12.96 million | Q2 2023: -$5.58 million | Q3 2023: -$6.09 million | Q1 2024: -$11.22 million | Q2 2024: -$28.19 million | Q3 2024: -$5.86 million | Q1 2025: -$14.86 million | Q2 2025: -$10.43 million | Q3 2025: -$13.43 million.
- Over the full 7 years of available data (2018 to 2024), Quince Therapeutics, Inc.'s Operating Income Loss has declined by 372.7%.
- Historical annual values: Fiscal year 2024: -$57.29 million | Fiscal year 2023: -$34.62 million | Fiscal year 2022: -$52.02 million | Fiscal year 2021: -$90.32 million | Fiscal year 2020: -$78.89 million | Fiscal year 2019: -$39.17 million | Fiscal year 2018: -$12.12 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: